LIVERPOOL, England (AP) — Arne Slot took a big step closer to becoming Liverpool's manager after the Premier League club reportedly agreed to pay Feyenoord about 11 million euros ($11.7 million) in compensation.
British and Dutch media reported that the clubs reached a verbal agreement on the compensation package, clearing the way for the 45-year-old Slot to succeed Jurgen Klopp after this season.
While British media pegged the compensation around 11 million euros, Dutch newspaper De Telegraaf said the figure could surpass 13 million euros. Slot has two years left on his contract with the Rotterdam club.
Klopp is leaving Liverpool after a spell of more than eight years in which he has won a full set of trophies including the Premier League and Champions League.
Neither club has commented. With the compensation package agreed, Liverpool can now negotiate contract terms with Slot.
On Friday, Klopp described the Anfield post as the “best job in the world.” He said he liked Slot’s style of soccer but has not been involved in the search process.
“If he’s the solution I’m more than happy," Klopp said. “It’s not up to me to judge these things, but it all sounds really good to me.”
At Feyenoord, Slot delivered the Dutch league title last season and the Dutch Cup this year.
Liverpool's manager Jurgen Klopp reacts during the English Premier League soccer match between Everton and Liverpool at the Goodison Park stadium in Liverpool, Britain, Wednesday, April 24, 2024. (AP Photo/Jon Super)
Arne Slot a step closer to Liverpool job as compensation deal reached with Feyenoord
FILE- Feyenoord's head coach Arne Slot reacts to his players during the Europa League play off, first leg soccer match between Feyenoord and Roma at De Kuip stadium in Rotterdam, Netherlands, Thursday, Feb. 15, 2024. Liverpool might have found its replacement for Jurgen Klopp. Feyenoord coach Arne Slot says his Dutch club is “negotiating” with Liverpool over his possible move to Anfield. Slot tells ESPN he is “still on hold" and “we have to wait for an agreement to be reached, but I have every confidence in that.” (AP Photo/Peter Dejong, File)
Arne Slot a step closer to Liverpool job as compensation deal reached with Feyenoord
WALTHAM, Mass.--(BUSINESS WIRE)--May 9, 2024--
In the highly regulated pharmaceutical industry, implementing the latest technologies to help bring medical breakthroughs to market is of critical importance. That is why Wolters Kluwer Health has collaborated with some of the leading pharmaceutical companies to bring intuitive and easy-to-use workflows to the Ovid ® research platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509872202/en/
Scaling up customizable solutions
The pharma and biotech industries rely on obtaining the latest, most comprehensive clinical information to effectively do their jobs. Automation and efficiency are imperative to manage the massive volumes of information within regulatory, clinical writing, medical affairs, pharmacovigilance, health economics and outcomes research, or publications groups. This allows different organizational functions to complete key tasks with speed and accuracy, such as leveraging hard-to-find data to generate study designs, substantiating findings for regulatory agencies, and gathering the latest information regarding disease management.
“Each pharmaceutical, life sciences and biomedical organization must adhere to strict regulatory guidelines, while also having unique needs for their specific business focus. Providing those institutions with an expert solution that is flexible, while continuously supplying authoritative information in a timely and digestible manner, is crucial,” saidRafael Sidi, Senior Vice President & General Manager of Health Research, Wolters Kluwer Health. “The Ovid research platform is uniquely positioned to support this industry, empowering researchers by putting essential information from a vast array of trusted resources at their fingertips.”
Improving workflow and productivity through understanding researchers’ tasks
Ovid medical research solutions enhance search precision and workflow speed to maximize research productivity. Teams improve their efficiency with more focused results, drug-specific keywording, and a clear path to the full text of relevant research. Additionally, the platform helps reduce administrative overhead, by freeing team members to spend more time on stakeholder engagement and regulatory requirements.
Wolters Kluwer worked with the world’s top pharmaceutical company to develop new enhancements in the Ovid research platform that will improve research automation and efficiency across the industry. New research tool updates include:
Learn more about the vital role that the Ovid research platform can play for pharma organizations and review this case study on how an international, rare drug manufacturer is currently leveraging the platform’s tools to accelerate their research.
For more information about Wolters Kluwer, please visit: www.wolterskluwer.com
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
Wolters Kluwer Health has collaborated with some of the leading pharmaceutical companies to bring intuitive and easy-to-use workflows to the Ovid® research platform (Photo: Business Wire)
